Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. President Trump's announcement of 'major' pharmaceutical tariffs has caused market turmoil and a decrease in industry value. Analysts predict increased costs for medicines and potential negative effects on patient drug access. Pharmaceutical companies are preparing for potential financial impacts as they brace for the implications of the upcoming tariffs on their operations and bottom line.The pharmaceutical market is witnessing a significant decline in value due to President Trump's tariffs, with billions in market cap being shed. Analysts forecast increased costs for medicines as a result of the tariffs, posing challenges for the traditionally recession-resistant industry. Intense competition between drug rivals is evident, with companies like Eli Lilly experiencing significant drops in value. Wacker Biotech is offering their services as a partner for advanced therapies, amidst warnings about China overtaking the US in biotech and FDA job cuts under Trump's administration. Various developments in the biopharmaceutical industry are also shaping the landscape. Job openings in the sector are highlighted, urging readers to subscribe to the Biospace newsletter for updates on news and trends.